Abstract: OBJECTIVE To investigate the clinical outcomes of penicilliosis marneffei (PSM) treated with different programs so as to provide guidance for effective clinical control of PSM. METHODS The clinical data were collected from 104 patients who were confirmed with Penicillium marneffei (PM) infection and were treated in the First Affiliated Hospital of Guangxi Medical University from Jan 2003 to Jan 2014.The influence on the prognosis was observed and compared among the different treatment programs. RESULTS Totally 104 patients were confirmed with PSM, with the confirmed rate 100.0%, of whom 45 were complete remission or partial remission,7 were improved, 41 died, and 11 lost to follow-up.Totally 92 patients received antifungal therapy, 38 patients were treated with amphotericin B combined with itraconazole, of whom 23 were complete remission, 2 were improved, 10 died, and 3 lost to follow-up.Totally 24 patients were treated with fluconazole combined with itraconazole, of whom 5 were complete remission or partial remission, 2 were improved, 16 died, and 1 lost to follow-up.Totally 15 patients were treated with itraconazole, of whom 8 were complete remission or partial remission, 2 were improved, 4 died, and 1 lost to follow-up.Totally 9 patients were treated with voriconazole, of whom 4 were completed remission or partial remission, no case was improved, 3 died, and 2 lost to follow-up.Totally 6 patients were given the combined therapy of amphotericin B, voriconazole, and itraconazole, of whom 2 were complete remission or partial remission, 1 was improved, 3 died, and no case lost to follow-up.As compared with the survival curve among the 5 treatment programs, the survival rate of the patients was higher in the amphotericin B combined with itraconazole group than in the fluconazole combined with itraconazole group (P=0.010), and there was no significant difference in the survival curve among the rest of groups. CONCLUSION The mortality rate of PSM is high.The amphotericin B combined with itraconazole is effective in treatment of PSM; however, as for the patients who have liver and kidney dysfunction or were not tolerant to amphotericin B, voriconazole has more advantages in safety and efficacy, fluoconazole is less effective in treatment of PSM.